[go: up one dir, main page]

PE20090957A1 - Moduladores de gamma secretasa - Google Patents

Moduladores de gamma secretasa

Info

Publication number
PE20090957A1
PE20090957A1 PE2008001303A PE2008001303A PE20090957A1 PE 20090957 A1 PE20090957 A1 PE 20090957A1 PE 2008001303 A PE2008001303 A PE 2008001303A PE 2008001303 A PE2008001303 A PE 2008001303A PE 20090957 A1 PE20090957 A1 PE 20090957A1
Authority
PE
Peru
Prior art keywords
diseases
secretasa
cycloalkyl
modulators
gamma modulators
Prior art date
Application number
PE2008001303A
Other languages
English (en)
Inventor
Zhaoning Zhu
Brian A Mckittrick
William J Greenlee
Robert D Mazzola
John P Caldwell
Xianhai Huang
Chad E Bennett
Hubert B Josien
Duane A Burnett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090957(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090957A1 publication Critical patent/PE20090957A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE W ES -S(O)-, -S(O)2- O -C(O)-; U ES UN ENLACE, -C(O)-, -O-, N(R5), C(R3)(R4); X ES -N(R14)- O -C(R6)(R7)-; LAS LINEAS DISCONTINUAS (---) REPRESENTAN ENLACES OPCIONALES; R1, R2, R3, R4, R5, R6, R7, R8, R9 Y R14 SON ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R10 ES CICLOALQUILO, CICLOALQUILAQUIL, HETEROARILO, ENTRE OTROS; R12 ES ARILO, HETEROARILALQUILO, -CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: A9, A10, A11, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE GAMMA SECRETASA Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL TALES COMO ENFERMEDADES NEURODEGENERATIVAS, ENFERMEDADES RELACIONADAS CON LA DEPOSICION DE PROTEINA AMILOIDE
PE2008001303A 2007-08-06 2008-08-04 Moduladores de gamma secretasa PE20090957A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95417807P 2007-08-06 2007-08-06

Publications (1)

Publication Number Publication Date
PE20090957A1 true PE20090957A1 (es) 2009-07-13

Family

ID=40032527

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001303A PE20090957A1 (es) 2007-08-06 2008-08-04 Moduladores de gamma secretasa

Country Status (10)

Country Link
US (1) US20110009392A1 (es)
EP (1) EP2185522A1 (es)
JP (1) JP2010535762A (es)
AR (1) AR068052A1 (es)
CA (1) CA2695543A1 (es)
CL (1) CL2008002308A1 (es)
MX (1) MX2010001506A (es)
PE (1) PE20090957A1 (es)
TW (1) TW200911266A (es)
WO (1) WO2009020580A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
AU2005297966B2 (en) 2004-10-26 2010-12-23 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
EP1953154A4 (en) 2005-11-24 2013-11-20 Eisai R&D Man Co Ltd CINNAMIDE COMPOUNDS OF MORPHOLINE TYPE
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
WO2009028588A1 (ja) 2007-08-31 2009-03-05 Eisai R & D Management Co., Ltd. 多環式化合物
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
EP2367826A4 (en) 2008-11-06 2012-07-04 Astrazeneca Ab MODULATORS OF THE PROTEIN -AMYLOID
UY32622A (es) * 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
AU2012243329B2 (en) 2011-04-13 2015-09-17 Merck Sharp & Dohme Corp. 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
EP2747769B1 (en) 2011-08-22 2017-08-02 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
DK3004079T3 (en) 2013-06-04 2018-04-16 Acturum Real Estate Ab PYRIMIDE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS
JP6396438B2 (ja) 2013-06-04 2018-09-26 アクチュラム・ライフ・サイエンス・アクチエボラーグ トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
JP6368776B2 (ja) 2013-06-04 2018-08-01 アクチュラム・ライフ・サイエンス・アクチエボラーグ トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
US11349879B1 (en) 2013-07-28 2022-05-31 Secureauth Corporation System and method for multi-transaction policy orchestration with first and second level derived policies for authentication and authorization
BR112017015693A2 (pt) 2015-02-03 2018-03-20 Pfizer ciclopropabenzofuranil piridopirazinadionas
CN105218457A (zh) * 2015-09-21 2016-01-06 山东大学 一种3,5,5’-三取代-2-乙内酰硫脲的制备方法
US10652248B2 (en) * 2016-07-28 2020-05-12 Molecula Corp. Systems and methods of managing data rights and selective data sharing
AR117715A1 (es) 2019-12-17 2021-08-25 Univ Nacional Del Litoral Unl Interferón hiperglicosilado con inmunogenicidad reducida
CN115716807A (zh) * 2022-11-25 2023-02-28 苏利制药科技江阴有限公司 一种(r)-1-n-boc-3-哌嗪甲酸甲酯的合成工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244739B2 (en) * 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
JP2007538024A (ja) * 2004-05-19 2007-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
EP1953154A4 (en) * 2005-11-24 2013-11-20 Eisai R&D Man Co Ltd CINNAMIDE COMPOUNDS OF MORPHOLINE TYPE

Also Published As

Publication number Publication date
CA2695543A1 (en) 2009-02-12
TW200911266A (en) 2009-03-16
JP2010535762A (ja) 2010-11-25
AR068052A1 (es) 2009-11-04
MX2010001506A (es) 2010-03-10
EP2185522A1 (en) 2010-05-19
US20110009392A1 (en) 2011-01-13
WO2009020580A1 (en) 2009-02-12
CL2008002308A1 (es) 2009-07-17

Similar Documents

Publication Publication Date Title
PE20090957A1 (es) Moduladores de gamma secretasa
CY1124284T1 (el) Ενωσεις σπειρο[3η-ινδολο-3,2'-πυρρολιδιν]-2(1η)-ονης και παραγωγα ως αναστολεις mdm2-p53
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20191532A1 (es) Compuestos heterociclicos como inmunomoduladores
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
PE20090363A1 (es) Moduladores de la gamma secretasa
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
PE20210129A1 (es) Compuestos de 4-azaindol
PE20190731A1 (es) Compuestos heterociclicos como inmunomoduladores
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
PE20010130A1 (es) Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
PE20171342A1 (es) Compuestos y su uso como inhibidores de bace
PE20070531A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PA8591701A1 (es) Derivados de pirrolopirimidina
AR066111A1 (es) Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
UY31638A1 (es) Furo[3,2-c]piridina y tieno[3,2-c]piridinas
PE20081882A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
ECSP056134A (es) Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3
PE20141000A1 (es) Ureas asimetricas y usos medicos de las mismas
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal

Legal Events

Date Code Title Description
FC Refusal